105 related articles for article (PubMed ID: 38863037)
1. BUB1 regulates non-homologous end joining pathway to mediate radioresistance in triple-negative breast cancer.
Sriramulu S; Thoidingjam S; Chen WM; Hassan O; Siddiqui F; Brown SL; Movsas B; Green MD; Davis AJ; Speers C; Walker E; Nyati S
J Exp Clin Cancer Res; 2024 Jun; 43(1):163. PubMed ID: 38863037
[TBL] [Abstract][Full Text] [Related]
2. BUB1 regulates non-homologous end joining pathway to mediate radioresistance in triple-negative breast cancer.
Sriramulu S; Thoidingjam S; Chen WM; Hassan O; Siddiqui F; Brown SL; Movsas B; Green MD; Davis AJ; Speers C; Walker E; Nyati S
bioRxiv; 2024 May; ():. PubMed ID: 38766122
[TBL] [Abstract][Full Text] [Related]
3. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Michmerhuizen AR; Chandler B; Olsen E; Wilder-Romans K; Moubadder L; Liu M; Pesch AM; Zhang A; Ritter C; Ward ST; Santola A; Nyati S; Rae JM; Hayes D; Feng FY; Spratt D; Wahl D; Eisner J; Pierce LJ; Speers C
Front Endocrinol (Lausanne); 2020; 11():35. PubMed ID: 32117061
[TBL] [Abstract][Full Text] [Related]
4. RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.
Pesch AM; Hirsh NH; Michmerhuizen AR; Jungles KM; Wilder-Romans K; Chandler BC; Liu M; Lerner LM; Nino CA; Ward C; Cobain EF; Lawrence TS; Pierce LJ; Rae JM; Speers CW
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34932500
[TBL] [Abstract][Full Text] [Related]
5. A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.
Dinkelborg PH; Wang M; Gheorghiu L; Gurski JM; Hong TS; Benes CH; Juric D; Jimenez RB; Borgmann K; Willers H
Breast Cancer Res Treat; 2019 Apr; 174(3):605-613. PubMed ID: 30607635
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
7. Fisetin induces DNA double-strand break and interferes with the repair of radiation-induced damage to radiosensitize triple negative breast cancer cells.
Khozooei S; Lettau K; Barletta F; Jost T; Rebholz S; Veerappan S; Franz-Wachtel M; Macek B; Iliakis G; Distel LV; Zips D; Toulany M
J Exp Clin Cancer Res; 2022 Aug; 41(1):256. PubMed ID: 35989353
[TBL] [Abstract][Full Text] [Related]
8. Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer.
Speers C; Zhao SG; Kothari V; Santola A; Liu M; Wilder-Romans K; Evans J; Batra N; Bartelink H; Hayes DF; Lawrence TS; Brown PH; Pierce LJ; Feng FY
Clin Cancer Res; 2016 Dec; 22(23):5864-5875. PubMed ID: 27225691
[TBL] [Abstract][Full Text] [Related]
9. CPNE1 predicts poor prognosis and promotes tumorigenesis and radioresistance via the AKT singling pathway in triple-negative breast cancer.
Shao Z; Ma X; Zhang Y; Sun Y; Lv W; He K; Xia R; Wang P; Gao X
Mol Carcinog; 2020 May; 59(5):533-544. PubMed ID: 32181526
[TBL] [Abstract][Full Text] [Related]
10. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
Tu X; Kahila MM; Zhou Q; Yu J; Kalari KR; Wang L; Harmsen WS; Yuan J; Boughey JC; Goetz MP; Sarkaria JN; Lou Z; Mutter RW
Mol Cancer Ther; 2018 Nov; 17(11):2462-2472. PubMed ID: 30166399
[TBL] [Abstract][Full Text] [Related]
11. Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple-negative breast cancer cells.
Choi E; Jeon KH; Lee H; Mun GI; Kim JA; Shin JH; Kwon Y; Na Y; Lee YS
Cancer Sci; 2024 Jun; 115(6):2036-2048. PubMed ID: 38613358
[TBL] [Abstract][Full Text] [Related]
12. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
13. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
15. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
16. Silencing of XRCC4 increases radiosensitivity of triple-negative breast cancer cells.
Wen Y; Dai G; Wang L; Fu K; Zuo S
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30842344
[TBL] [Abstract][Full Text] [Related]
17. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy.
Mehta M; Basalingappa K; Griffith JN; Andrade D; Babu A; Amreddy N; Muralidharan R; Gorospe M; Herman T; Ding WQ; Ramesh R; Munshi A
Oncotarget; 2016 Oct; 7(40):64820-64835. PubMed ID: 27588488
[TBL] [Abstract][Full Text] [Related]
18. PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling.
Li B; Huang L; Ruan J
Rev Invest Clin; 2024; 76(1):45-59. PubMed ID: 38442372
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
20. Combined Aurora Kinase A and CHK1 Inhibition Enhances Radiosensitivity of Triple-Negative Breast Cancer Through Induction of Apoptosis and Mitotic Catastrophe Associated With Excessive DNA Damage.
Li C; Liao J; Wang X; Chen FX; Guo X; Chen X
Int J Radiat Oncol Biol Phys; 2023 Dec; 117(5):1241-1254. PubMed ID: 37393021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]